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background: In patients with atrial fibrillation (AF), sex differences were observed with regards to warfarin treatment, with women having a higher 
risk of stroke compared to men. With the emergence of dabigatran as an alternative to warfarin, we aimed to compare sex differences in utilization 
patterns of dabigatran the associations with stroke, bleeding and myocardial infarction (MI) outcomes.
methods: We conducted a population-based cohort study of patients with AF using administrative data in Quebec, Canada, 1999-2012. Men and 
women who filled a prescription for dabigatran (110 and 150 mg bid) were compared with matched warfarin users with respect to their rates of 
stroke, bleeding and MI events. Propensity score adjusted models were used.
results: The cohort comprised of 30,030 women (50.2%) and 29,816 men (49.8%). Women had a higher baseline stroke risk and lower baseline 
bleeding risk compared to men. Women fill more prescriptions for the lower dabigatran dose compared to men (adjusted OR: 1.38, 95%CI: 1.23, 
1.54). In multivariable Cox regression analyses adjusted for the relevant propensity scores, in women, dabigatran was not associated with a 
difference in the risk of stroke, bleeding and MI compared to warfarin. In men, a trend toward lower risk of bleeding (HR 0.86, 95%CI: 0.70, 1.04; HR 
0.83, 95%CI: 0.67, 1.03, for the 110 and 150 mg, respectively), and a higher risk of MI (HR: 1.42, 95%CI: 0.93, 2.15; HR: 1.44, 95%CI: 0.88, 2.35, 
for the 110 and 150 mg, respectively), was observed when both doses of dabigatran were compared with warfarin. None of the interaction terms 
between sex and dabigatran use were significant for any outcomes.
conclusions: While both men and women treated with dabigatran gain similar stroke protection to warfarin, sex differences were observed with 
regards to bleeding and MI, with men treated with dabigatran having a tendency toward less bleeding events and more MIs compared with warfarin.
